SCHEMBL2736620

SCHEMBL2736620

Cn1c2c(cc(CSc3nc4ccccc4o3)c1=O)CCCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.48
SMN1; SMN2 Q16637 5/20 0.47
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
TSHR P16473 5/20 0.46
MAPT P10636 4/20 0.46
MAPK1 P28482 4/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 3/20 0.46
HPGD P15428 6/20 0.45
ALDH1A1 P00352 6/20 0.45
HSD17B10 Q99714 3/20 0.45
ALOX15 P16050 2/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2760202 0.86 ELANE (0.46) ELANESMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL2736619 0.79 LTA4H (0.41) ELANE
SCHEMBL2736540 0.73 CNR2 (0.51) MAPT
SCHEMBL2736610 0.73 ELANE (0.57) ELANESMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL4213126 0.69 MAPT (0.62) ELANESMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL217275 0.68 ELANE (0.54) ELANESMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL2760203 0.67 CNR2 (0.53)
SCHEMBL16609345 0.67 ELANE (0.61) ELANESMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL2736618 0.66 CNR2 (0.41) MAPTLMNACYP2C19
SCHEMBL27207542 0.65 RAB9A (0.50) ELANESMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R ELANE 4607/4885SMN1; SMN2 4652/4885NPC1 4500/4885
US-20080312292-A1 Antipruritics CNR1, CNR2, OPRL1 ELANE 512/4885SMN1; SMN2 3366/4885NPC1 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.